Patients with certain plaque psoriasis treated with 300mg of Cosentyx for only four weeks reported in a questionnaire improvements in life quality, Novartis said Monday.
Novartis said that results from a pooled analysis of four Phase 3 clinical trials showed patients with moderate-to-severe plaque psoriasis (PsO) treated with Cosentyx (secukinumab) 300 mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnaire as early as week 4 when compared to placebo in patients who reported problems at baseline.
The results were presented at the 15thh Annual Maui Derm for Dermatologists 2019, Novartis said in the press release.
Steven R. Feldman, Wake Forest School of Medicine, was referred to as saying: “Moderate-to-severe plaque psoriasis can impact every aspect of a person’s life. These findings suggest that helping patients feel better through improved quality of life and ability to function should be a goal as important as skin clearance in psoriasis management.”
By Dino Mustafić